The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2020 | GO-FLAG: bridge therapy to allo-SCT in R/R AML
Ivan Moiseev, MD, PhD, First Saint Petersburg State Medical University, Saint Petersburg, Russia, reports on the use of the GO-FLAG regimen (gemtuzumab ozogamicin with fludarabine, cytarabine, and G-CSF), as a bridge therapy to allogeneic stem cell transplantation (allo-SCT) in relapsed/refractory (R/R) acute myeloid leukemia (AML) patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
